title: A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
abstract: We conducted a phase II trial of intraperitoneal (IP) cisplatin (DDP) and etoposide (VP-16) in stage III and IV newly diagnosed ovarian carcinoma patients with residual disease of any size. Twenty-three patients were entered, 19 had stage III and four stage IV disease. DDP 200 mg/m2 and VP-16 350 mg/m2 were given in 2 L saline IP via a Port-A-Cath (Pharmacia-Deltec, St Paul, MN). Sodium thiosulfate 4 g/m2 was given intravenously (IV) just before the start of IP instillation, and continued as a constant IV infusion of 2 g/m2/hr IV for a total of 6 hours. Treatment was given once every 4 weeks; six cycles of therapy were planned. Thirteen patients (56%) were in complete clinical remission at the end of treatment (normal physical exam, computed tomographic [CT] scan, CA-125, and peritoneal cytology). Seven of these 13 underwent a second-look laparotomy: three (13%) were in pathologic complete remission and four (17%) had microscopic disease only. Projected survival is 68% at 27 months, with 10 patients being alive and continuously free of disease. There was a very rapid fall in mean CA-125 to within normal limits at the end of the second course of treatment. The major toxicity was myelosuppression with median nadir WBC, granulocyte, and platelet counts of 2,600, 896, and 205,000/microL, respectively. There was no cumulative renal damage, anemia, hypomagnesemia, or chemical peritonitis. Neurotoxicity was similar to that observed with IV dosing. We conclude that therapy with the IP DDP/VP-16/IV thiosulfate regimen, in which all cytotoxic drugs are given only by the IP route, produces less anemia and renal damage than standard IV DDP-containing regimens, and that survival with this regimen appears to be at least as good as that produced by IV programs.
authors.affiliation: Department of Medicine, University of California, San Diego, La Jolla 92093.
authors.forename: S B
authors.initials: SB
authors.lastname: Howell
authors.forename: S
authors.initials: S
authors.lastname: Kirmani
authors.forename: W E
authors.initials: WE
authors.lastname: Lucas
authors.forename: S
authors.initials: S
authors.lastname: Zimm
authors.forename: R
authors.initials: R
authors.lastname: Goel
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: M C
authors.initials: MC
authors.lastname: Horton
authors.forename: L
authors.initials: L
authors.lastname: McVey
authors.forename: J
authors.initials: J
authors.lastname: Morris
authors.forename: R J
authors.initials: RJ
authors.lastname: Weiss
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral / Q000379:methods; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D016019:Survival Analysis; D013885:Thiosulfates / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D013885:Thiosulfates; D005047:Etoposide; C017717:sodium thiosulfate; D002945:Cisplatin